(E)-methyl 3-(2-amino-5-(tert-butyl)phenyl)acrylate | 231296-92-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-methyl 3-(2-amino-5-(tert-butyl)phenyl)acrylate
• 英文别名: methyl (E)-3-(2-amino-5-(tert-butyl)phenyl)acrylate；methyl (2E)-3-(2-amino-5-tert-butylphenyl)acrylate；methyl trans-5-tert-butyl-2-aminocinnamate；methyl (E)-3-(2-amino-5-tert-butylphenyl)prop-2-enoate
• CAS: 231296-92-7
• 化学式: C₁₄H₁₉NO₂
• 分子量: 233.31
• InChiKey: PFLRQSPRCFOYFC-VMPITWQZSA-N

物化性质

• 沸点：
  360.6±37.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-methyl 3-(2-amino-5-(tert-butyl)phenyl)acrylate 在 吡啶 、 碘苯二乙酸 、 氟化氢吡啶 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 16.33h， 生成 methyl (2E)-3-(5′-fluoro-2′-[N-(p-toluenesulfonyl)amino]phenyl)prop-2-enoate
  参考文献：
  名称：

  N-芳基磺酰胺的氧化氟化

  摘要：

  我们报告了N-芳基磺酰胺的晚期氧化亲核氟化，一类化合物到目前为止尚未被视为4-氟苯基磺酰胺的前体。通过在苯胺上安装对位叔丁基取代基，在HF·吡啶和PIDA存在下区域选择性地发生氧化氟化。已显示出该方法对于多种邻-和间-官能化的N-芳基磺酰胺具有良好的产率，并且已适于在载体添加的条件下进行放射性氟化以产生4- [ 18 F]氟苯基磺酰胺。

  DOI：

  10.1016/j.jfluchem.2015.07.030
• 作为产物：
  描述：

  2-溴-4-叔丁基苯胺 生成 (E)-methyl 3-(2-amino-5-(tert-butyl)phenyl)acrylate
  参考文献：
  名称：

  2,3-substituted indole compounds as anti-inflammatory and analgesic agents

  摘要：

  这项发明提供了以下式的化合物： 或其药学上可接受的盐，其中Z为OH、C1-6烷氧基、—NR2R3或杂环；Q从以下中选择：(a) 可选择取代的苯基，(b) 可选择取代的含有一个、两个、三个或四个氮原子的6-成员单环芳基，(c) 可选择取代的含有O、S和N中选择的一个杂原子的5-成员单环芳基，并且除所述杂原子外还可选择含有一个、两个或三个氮原子，(d) 可选择取代的C3-7环烷基和(e) 可选择取代的苯并噻吩杂环；R1为氢、C1-4烷基或卤素；R2和R3独立地为氢、OH、C1-4烷氧基、C1-4烷基或用卤素、OH、C1-4烷氧基或CN取代的C1-4烷基；X独立地从H、卤素、C1-4烷基、卤素取代的C1-4烷基、OH、C1-4烷氧基、卤素取代的C1-4烷氧基、C1-4烷基硫醚、NO2、NH2、二-(C1-4烷基)氨基和CN中选择；n为0、1、2、3和4。 这项发明还提供了一种用于治疗前列腺素参与的医疗状况的药物组合物。

  公开号：

  US06608070B1

文献信息

• Visible‐Light‐Driven Isocyanide Insertion to <i>o</i> ‐Alkenylanilines: A Route to Isoindolinone Synthesis
  作者：Anjali Dahiya、Bubul Das、Ashish Kumar Sahoo、Bhisma K. Patel

  DOI：10.1002/adsc.202101431

  日期：2022.3

  intermolecular radical insertion of isocyanides to electron-deficient o-alkenylanilines leading to isoindolinone is reported. Deuterium (D2O) and H2O18 labelling experiments suggest H and O incorporation in the product. The formation of an N-centered radical (NCR) via stepwise PT/ET process was confirmed by radical trapping experiments, photoluminescence, cyclic voltammetry and DFT studies. This photo cascade methodology

  报道了可见光介导的异氰化物分子间自由基插入到缺电子的o-烯基苯胺，导致异吲哚啉酮。氘 (D 2 O) 和 H 2 O 18标记实验表明产品中含有 H 和 O。通过自由基捕获实验、光致发光、循环伏安法和 DFT 研究证实了通过逐步 PT/ET 过程形成N中心自由基 (NCR) 。这种光级联方法总体上是一种氧化还原中性工艺，具有无金属条件和广泛的基材范围（32 个示例）。GABA 受体拮抗剂类似物的合成显示了该方法的实用性。
• Transformable Transient Directing Group-Assisted C(sp²)–H Activation: Synthesis and Late-Stage Functionalizations of <i>o</i>-Alkenylanilines
  作者：Bubul Das、Anjali Dahiya、Ashish Kumar Sahoo、Bhisma K. Patel

  DOI：10.1021/acs.joc.2c01626

  日期：2022.10.7

  The isocyanate group in aryl isocyanates serves as a transformable transient directing group in a Ru(II)-catalyzed ortho olefination leading to o-alkenylanilines. In alcoholic solvents, aryl isocyanates are transformed into carbamates, which initiate the insertion of acrylates via o-C–H activation. In particular, tAmOH serves the dual role of solvent-cum transient directing mediator. The o-alkenylanilines

  异氰酸芳基酯中的异氰酸酯基团在 Ru(II) 催化的邻位烯化反应中用作可转化的瞬态导向基团，生成邻烯基苯胺。在醇溶剂中，芳基异氰酸酯转化为氨基甲酸酯，从而通过o -C-H 活化引发丙烯酸酯的插入。特别是，t AmOH 起到溶剂兼瞬态引导介体的双重作用。通过 Pd(II) 催化的 C-H 官能化，使用芳基碘化物作为偶联配偶体，将邻烯基苯胺转化为氮杂香豆素，随后转化为 C-4 芳基取代的氮杂香豆素。
• Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure–activity relationship for anti-inflammatory drug
  作者：Shigeo Hayashi、Naomi Ueno、Akio Murase、Yoko Nakagawa、Junji Takada

  DOI：10.1016/j.ejmech.2012.01.053

  日期：2012.4

  Cyclooxygenase (COX) is a key rate-limiting enzyme for prostaglandin (PG) production cascades in the human body. The mechanisms of both the anti-inflammation effects and the side-effects of traditional COX inhibitors are associated with the existence of two COX isoforms. Thus while COX-1 is predominantly expressed ubiquitously and constitutively, and it serves a housekeeping role in processes such as gastrointestinal (GI) mucosa protection, COX-2 is absent or exhibits a low level of expression in most tissues, and is highly upregulated in response to endotoxin, virus, inflammatory or tissue-injury stimuli/signals, and tumour promoter in the various types of organs, tissues, and cells. Furthermore, COX-2 contribution to PGE(2) and PGI(2) production evokes and sustains systemic or peripheral inflammatory disease, but it is not involved in the COX-1-mediated GI tract events. Also, hypersensitivity of aspirin owing to its inhibitory action against COX-1 is a significant concern clinically. Consequently, highly selective COX-2 inhibitors have been needed for the treatment of inflammatory- and inflammation related-diseases that include pyrexia, inflammation, pain, rheumatoid arthritis, osteoarthritis, and cancers. In this study, a series of novel [2-[(4-substituted or 4,5-disubstituted)-pyridin-2-yl]carbonyl}-(5- or 6-substituted or 5,6-disubstituted)-1H-indol-3-yl]acetic acid analogues was designed, synthesized, and evaluated to identify potent and selective COX-2 inhibitors as potential agents against inflammatory diseases. As significant findings, the present study clarified unique structure activity relationship of the analogues toward potent and selective COX-2 inhibition in vitro, and identified 2-6-fluoro-2-[4-methyl-2-pridinyl)carbonyl]-1H-indol-3-yl}acetic acid as a potent and selective COX-2 inhibitor in vitro that demonstrated orally potent anti-inflammation efficacy against carrageenan-induced oedema formation in the foot of SPF/VAF male SD rats as a peripheral inflammation model in vivo. (C) 2012 Elsevier Masson SAS. All rights reserved.
• 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS
  申请人：PFIZER INC.

  公开号：EP1045833B1

  公开（公告）日：2005-11-02
• US6608070B1
  申请人：——

  公开号：US6608070B1

  公开（公告）日：2003-08-19